STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #694 by analyst upside · 2026-06-27
CRNX
Crinetics Pharmaceuticals, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+126.5%
implied upside to consensus target
Current Price $36.7
Consensus Target $83.14
Bull Target $97.0
Bear Target $55.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
1
Sell
0
52-Week Low $25.83
52-Week High $57.99
YTD Return -21.5%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -8.7x
EPS (TTM) $-5.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $18M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $25.83
52-Week High $57.99
Current Price $36.7
Bear Target $55.0
Bull Target $97.0
● Now $36.7 ● Target $83.14
TRADING DATA
Avg Volume 1.2M
YTD Return -21.5%
Analyst Count 14
Consensus Buy
Upside to Target +126.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Crinetics Pharmaceuticals, Inc. (CRNX) is currently trading at $36.7 with a Wall Street consensus price target of $83.14, implying potential upside of 126.5% over the next 12 months. 14 analysts currently cover CRNX, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $97.0, while the most cautious has a target of $55.0.

CRNX operates in the Healthcare sector with a market capitalisation of $4B. The stock is down 21.5% year-to-date and is currently trading near the lower end of its 52-week range of $25.83 – $57.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CRNX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-15 31% win rate (48 calls)
Citizens reit
Market Outperform → Market Outperform 2026-06-11 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-15 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2026-05-11 14% win rate (7 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-28 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-03-02 Building track record
Goldman Sachs ↑ Upgrade
Neutral → Buy 2026-01-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
21/30
Consensus clarity
7/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →